NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

374.20 1.80 (0.48%)

28.59% Gain from 52W Low

3.2M NSE+BSE Volume

NSE 11 Jul, 2025 3:31 PM (IST)

50,029.2

Market Cap

Market Leader

1.2

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

30 Dec 2020

374.20

0.48%

Company Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We have increased our target price to INR 505 (PEx 32x to FY23E earnings).

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

02 Nov 2020

374.20

0.48%

Biocon Ltd is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immune suppressants and anti-diabetic drugs.

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

28 Oct 2020

374.20

0.48%

BIOCON LTD

Buy: Biocon Ltd.

Target

Geojit BNP Paribas

Outlook remains intact on new product launches, strong pipeline and limited competition in Biosimilars. Additionally, demographic changes will help drive demand across products. Hence, we maintain our BUY...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

26 Oct 2020

374.20

0.48%

Result Update:Biocon

Buy: Biocon Ltd.

Axis Direct

Biocon' Q2FY21 revenue grew by 11% vs. our expectation of 15% due to supply chain bottleneck and lower takeoff biosimilars' business in new geographies (covid-19 lockdown). EBITDA margins (22%) decreased by 400 bps on YoY due high R&D; expenses, frorex losses and other expenses.

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

23 Oct 2020

374.20

0.48%

Biocon

Buy: Biocon Ltd.

Sharekhan

Q2FY2021 was a soft quarter for Biocon. Revenues from operations grew by 11% y-o-y to Rs 1,745 crore. Adjusted PAT rose by 10.3% y-o-y to Rs. 173.8 crore. Improving traction in existing biosimilars, likely pick up in Semglee, geographical expansion are the key growth drivers for Biologics segment. Biocon has retained its guidance for $1 billion in revenues from the biologics segment...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

23 Oct 2020

374.20

0.48%

Biocon

Buy: Biocon Ltd.

Target

ICICI Securities Limited

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

23 Oct 2020

374.20

0.48%

Operational challenges impact performance

Neutral: Biocon Ltd.

Target

Motilal Oswal

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

28 Sep 2020

374.20

0.48%

Pick of the Week:28 SEP 2020

Buy: Biocon Ltd.

Axis Direct

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

27 Jul 2020

374.20

0.48%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

Biocon reported a muted set of numbers for Q1FY21 with revenues growing at 14% on annual comparison but EBIDTA contracted by~6% and PAT by 27% on back of rising costs of Biologics business and higher R&D; spends.

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Is Biocon Ltd. worth buying?

721 Votes:

Buy 75.03%

Sell 16.23%

Hold 8.74%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf